EFFICACY OF INFLIXIMAB IN PATIENT WITH UNFAVORABLE CLINICAL COURSE OF JUVENILE RHEUMATOID ARTHRITIS
The article presents a case report of aggressive rapidly progressive severe polyarticular juvenile rheumatoid arthritis (JRA) resistant to standard immunosuppressive treatment. Patient with extra-early (up to 6 months) arthritis was successfully treated with genetically engineered biological agent i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2011-05-01
|
| Series: | Voprosy Sovremennoj Pediatrii |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/630 |
| Summary: | The article presents a case report of aggressive rapidly progressive severe polyarticular juvenile rheumatoid arthritis (JRA) resistant to standard immunosuppressive treatment. Patient with extra-early (up to 6 months) arthritis was successfully treated with genetically engineered biological agent infliximab. Pain decreased significantly after first injection of a drug, the second injection resulted in decrease of laboratory activity, third one completely stopped exudative lesion of joints, morning stiffness, and restored functional activity of a child. Thus, after 6 months the disease was transferred to inactive phase, motions of joints restored, there was no need in nonsteroid anti-inflammatory drugs. Cardiovascular symptoms stopped as well. The case report showed high efficacy of tumor necrotizing factor _ blocker infliximab in patients with aggressive clinical course and markers of unfavorable prognosis at very early stages of JRA before irreversible lesions of joints happen.Key words: children, early juvenile rheumatoid arthritis, infliximab, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2011; 10 (3): 157–165) |
|---|---|
| ISSN: | 1682-5527 1682-5535 |